Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis.

AIM Organic anion-transporting polypeptides OATP1B1 and OATP1B3 are sinusoidal membrane transporters mediating liver uptake of a wide range of substrates including conjugated and unconjugated bilirubin, xenobiotics and drugs. Absence of OATP1Bs in the liver causes Rotor syndrome. Our aim was to correlate OATP1B expression with hyperbilirubinemia in common liver diseases. METHODS Immunoreactivity of five antibodies against human OATP1Bs was tested on frozen and formalin-fixed paraffin-embedded liver tissue of mouse strains transgenic for SLCO1B1 or SLCO1B3 and on human specimens. The proportion of hepatocytes expressing OATP1Bs was then assessed immunohistologically in formalin-fixed paraffin-embedded liver samples obtained from patients with hepatocellular and primary biliary liver diseases. UGT1A1 promoter TATA-box and SLCO1B1 rs4149056 genotyping was performed to rule out individuals predisposed to hyperbilirubinemia. RESULTS The most specific detection of OATP1B3 was achieved with the H-52 (sc-98981) antibody. OATP1B1 was specifically recognized with the ESL (ab15441) anti-OATP1B1 antibody, but only in frozen sections. The MDQ (ab15442) anti-OATP1B1 antibody cross-reacted with both OATP1B proteins in liver tissue of the transgenic mouse strains. Expression of the OATP1B proteins was decreased in advanced liver diseases and inversely correlated with serum bilirubin levels. The reduction was more pronounced in advanced primary biliary diseases (1.9±1.1 vs. 2.7±0.6; P=0.009). CONCLUSIONS Down-regulation of OATP1B proteins may contribute to pathogenesis of jaundice accompanying advanced cholestatic liver diseases.

[1]  D. Keppler.  The Roles of MRP2, MRP3, OATP1B1, and OATP1B3 in Conjugated Hyperbilirubinemia , 2014, Drug Metabolism and Disposition.

[2]  B. Hagenbuch,et al.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies , 2012, British journal of pharmacology.

[3]  E. van de Steeg,et al.  Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. , 2012, The Journal of clinical investigation.

[4]  G. Akpinar,et al.  Neonatal hyperbilirubinemia and organic anion transporting polypeptide-2 gene mutations. , 2011, American journal of perinatology.

[5]  P. Neuvonen,et al.  Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.

[6]  E. van de Steeg,et al.  Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. , 2010, The Journal of clinical investigation.

[7]  M. Niemi,et al.  Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.

[8]  G. Abecasis,et al.  Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. , 2009, Human Molecular Genetics.

[9]  E. van de Steeg,et al.  Methotrexate Pharmacokinetics in Transgenic Mice with Liver-Specific Expression of Human Organic Anion-Transporting Polypeptide 1B1 (SLCO1B1) , 2009, Drug Metabolism and Disposition.

[10]  P. Neuvonen,et al.  The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. , 2008, British journal of clinical pharmacology.

[11]  M. Ho,et al.  Expression of Hepatocyte Transporters and Nuclear Receptors in Children With Early and Late-Stage Biliary Atresia , 2008, Pediatric Research.

[12]  Wei Zhang,et al.  OATP1B1 POLYMORPHISM IS A MAJOR DETERMINANT OF SERUM BILIRUBIN LEVEL BUT NOT ASSOCIATED WITH RIFAMPICIN‐MEDIATED BILIRUBIN ELEVATION , 2007, Clinical and experimental pharmacology & physiology.

[13]  M. Trauner,et al.  Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. , 2007, Biochimica et biophysica acta.

[14]  D. Keppler,et al.  The apical conjugate efflux pump ABCC2 (MRP2) , 2007, Pflügers Archiv - European Journal of Physiology.

[15]  R. Kim,et al.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. , 2006, Gastroenterology.

[16]  J. Wijnholds,et al.  Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. , 2006, Journal of hepatology.

[17]  A. Klein-Szanto,et al.  Analysis of the In Vivo Functions of Mrp3 , 2005, Molecular Pharmacology.

[18]  Y. Sugiyama,et al.  Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[19]  S. Vavricka,et al.  The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. , 2004, Journal of hepatology.

[20]  Peter J. Meier,et al.  Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties , 2004, Pflügers Archiv.

[21]  D. Keppler,et al.  Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. , 2003, Journal of hepatology.

[22]  K. Zatloukal,et al.  Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. , 2003, Journal of hepatology.

[23]  D. Keppler,et al.  Detection of the Human Organic Anion Transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in Liver and Hepatocellular Carcinoma , 2003, Laboratory Investigation.

[24]  G. Kullak-Ublick,et al.  Hepatocyte nuclear factor 1α: A key mediator of the effect of bile acids on gene expression , 2003 .

[25]  U. Beuers,et al.  Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. , 2001, Liver.

[26]  T. Abe,et al.  LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. , 2001, Gastroenterology.

[27]  K. Zatloukal,et al.  Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases , 2001, Hepatology.

[28]  D. Keppler,et al.  Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide* , 2000, The Journal of Biological Chemistry.

[29]  R. Stauber,et al.  [New molecular aspects of cholestatic liver diseases]. , 1999, Zeitschrift fur Gastroenterologie.

[30]  H. Yawo,et al.  Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1* , 1999, The Journal of Biological Chemistry.

[31]  C. Gartung,et al.  Molecular regulation of sinusoidal liver bile acid transporters during cholestasis. , 1997, The Yale journal of biology and medicine.

[32]  I. Szántay,et al.  [The rotor syndrome]. , 1983, Leber, Magen, Darm.

[33]  A. Schinkel,et al.  Cancer Therapy : Preclinical In fl uence of Human OATP 1 B 1 , OATP 1 B 3 , and OATP 1 A 2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice , 2013 .

[34]  G. Kullak-Ublick,et al.  Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. , 2003, Hepatology.

[35]  J. Boyer,et al.  Molecular Alterations in Hepatocyte Transport Mechanisms in Acquired Cholestatic Liver Disorders , 2000, Seminars in liver disease.

[36]  D. Keppler,et al.  A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. , 2000, American journal of physiology. Gastrointestinal and liver physiology.